<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Study the effects of exenatide (EXE) plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (ROSI) on beta-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> on <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their <z:chebi fb="0" ids="6801">metformin</z:chebi> regimen and received either EXE 10 microg b.i.d </plain></SENT>
<SENT sid="2" pm="."><plain>(n = 45), ROSI 4 mg b.i.d </plain></SENT>
<SENT sid="3" pm="."><plain>(n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d </plain></SENT>
<SENT sid="4" pm="."><plain>(n = 47) </plain></SENT>
<SENT sid="5" pm="."><plain>Seventy-three participants underwent clamp procedures to quantitate insulin secretion and insulin sensitivity </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS A1C declined in <z:hpo ids='HP_0000001'>all</z:hpo> groups (P &lt; 0.05), but decreased most with EXE+ROSI (EXE+ROSI, -1.3 +/- 0.1%; ROSI, -1.0 +/- 0.1%, EXE, -0.9 +/- 0.1%; EXE+ROSI vs. EXE or ROSI, P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>ROSI resulted in <z:mp ids='MP_0005456'>weight gain</z:mp>, while EXE and EXE+ROSI resulted in <z:hpo ids='HP_0001824'>weight loss</z:hpo> (EXE, -2.8 +/- 0.5 kg; EXE+ROSI, -1.2 +/- 0.5 kg; ROSI, + 1.5 +/- 0.5 kg; P &lt; 0.05 between and within <z:hpo ids='HP_0000001'>all</z:hpo> groups) </plain></SENT>
<SENT sid="8" pm="."><plain>At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Insulin sensitivity (M value) was significantly higher in EXE+ROSI versus EXE (P = 0.014) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Therapy with EXE+ROSI offset the <z:mp ids='MP_0005456'>weight gain</z:mp> observed with ROSI and elicited an additive effect on glycemic control with significant improvements in beta-cell function and insulin sensitivity </plain></SENT>
</text></document>